Early breast cancer patients with low levels of HER2 expression benefit more from the cancer vaccine E75

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1635, 2008-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2/neu (E75) vaccine reduces breast cancer recurrence

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Paclitaxel benefit in breast cancer linked to HER2 expression

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Serum Her-2/neu and Survivin Levels and Their Relationship to Histological Parameters in Early-stage Breast Cancer

By Goksel G   Taneli F   Uslu R   Ulman C   Dinc G   Coskun T   Kandiloglu AR  

The Journal of International Medical Research, Vol. 35, Iss. 2, 2007-03 ,pp. : 165-172

Field House Publishing

Access to resources Recommend Favorite

The HER2 CISH pharmDx ™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

By Foged Niels T   Brügmann Anja   Jørgensen Jan T  

Expert Review of Molecular Diagnostics, Vol. 13, Iss. 3, 2013-04 ,pp. : 233-242

Informa Healthcare

Access to resources Recommend Favorite

Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

By Zelnak Amelia B.   Wisinski Kari B.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 17-24

Blackwell Publishing

Access to resources Recommend Favorite